CLINICAL DRUG INVESTIGATION

Scope & Guideline

Transforming insights into impactful drug therapies.

Introduction

Welcome to your portal for understanding CLINICAL DRUG INVESTIGATION, featuring guidelines for its aims and scope. Our guidelines cover trending and emerging topics, identifying the forefront of research. Additionally, we track declining topics, offering insights into areas experiencing reduced scholarly attention. Key highlights include highly cited topics and recently published papers, curated within these guidelines to assist you in navigating influential academic dialogues.
LanguageEnglish
ISSN1173-2563
PublisherADIS INT LTD
Support Open AccessNo
CountryUnited Kingdom
TypeJournal
Convergefrom 1995 to 2024
AbbreviationCLIN DRUG INVEST / Clin. Drug Invest.
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND

Aims and Scopes

The journal 'Clinical Drug Investigation' focuses on clinical research related to drug efficacy, safety, and pharmacoeconomics. It aims to provide insights into the clinical use of medications across various therapeutic areas, emphasizing real-world evidence and systematic evaluations.
  1. Pharmacoeconomic Evaluations:
    The journal frequently publishes studies assessing the cost-effectiveness of drug therapies, providing valuable insights for healthcare decision-makers.
  2. Clinical Safety and Efficacy Studies:
    There is a strong emphasis on clinical trials and observational studies that evaluate the safety and efficacy of new and existing medications across various conditions.
  3. Real-World Evidence:
    Research includes real-world data that assess the effectiveness and safety of treatments in diverse populations, enhancing the understanding of drug performance outside controlled clinical trial settings.
  4. Systematic Reviews and Meta-Analyses:
    The journal includes comprehensive reviews and meta-analyses that synthesize existing literature, providing critical evaluations of treatment options and their outcomes.
  5. Biosimilars and Novel Therapies:
    A notable focus is on studies related to biosimilars and novel therapeutic agents, reflecting the evolving landscape of drug development and clinical application.
The journal 'Clinical Drug Investigation' reflects emerging trends in clinical research, particularly in the context of evolving healthcare needs, treatment paradigms, and regulatory landscapes. Recent themes indicate a shift towards more comprehensive evaluations of drug therapies.
  1. Real-World Effectiveness Studies:
    There is a growing trend towards publishing studies that assess the real-world effectiveness of drugs, emphasizing the importance of understanding how treatments perform in everyday clinical practice.
  2. Cost-Effectiveness Analyses:
    Increasingly, research articles are focusing on the economic evaluations of new therapies, highlighting the importance of cost-effectiveness in healthcare decision-making.
  3. Biosimilar Research:
    As the market for biosimilars expands, the journal is seeing a rise in studies examining the safety, efficacy, and economic implications of biosimilar therapies.
  4. Machine Learning and Predictive Modeling:
    Emerging methodologies such as machine learning for predictive modeling in pharmacotherapy are gaining traction, reflecting advancements in data analytics and personalized medicine.
  5. Impact of COVID-19 on Drug Utilization:
    The effects of the COVID-19 pandemic on drug utilization patterns and treatment outcomes represent an emerging area of interest, as researchers seek to understand the long-term implications of the pandemic on healthcare.

Declining or Waning

While the journal maintains a robust focus on several core areas, some themes have shown a decline in prominence over recent years, indicating a shift in research priorities and interests within the clinical drug investigation community.
  1. Traditional Pharmacotherapy Studies:
    There has been a noticeable decrease in publications focused solely on traditional pharmacotherapy studies without a comparative or economic angle, as the field increasingly values integrated approaches.
  2. Single-Center Trials:
    Research originating from single-center trials appears to be waning, with a preference shifting towards multicenter studies that provide broader applicability and generalizability of findings.
  3. Basic Pharmacokinetics Studies:
    Studies purely focusing on basic pharmacokinetics without clinical application or implications are less frequently published, as the journal emphasizes translational research that connects pharmacokinetics with therapeutic outcomes.

Similar Journals

Journal of Aerosol Medicine and Pulmonary Drug Delivery

Empowering respiratory care with breakthrough findings.
Publisher: MARY ANN LIEBERT, INCISSN: 1941-2711Frequency: 6 issues/year

The Journal of Aerosol Medicine and Pulmonary Drug Delivery, published by MARY ANN LIEBERT, INC, is a distinguished journal dedicated to advancing the field of aerosol medicine and pharmacology. With an ISSN of 1941-2711 and E-ISSN 1941-2703, the journal has established itself as an essential resource for researchers and professionals specializing in pharmaceutical sciences and pulmonary medicine. Ranking in the Q2 category across multiple disciplines, including Pharmaceutical Science and Pulmonary and Respiratory Medicine, it holds notable Scopus rankings, with a percentile of 78th in Pulmonary and Respiratory Medicine. The journal offers open access options, ensuring that cutting-edge research is readily available to a global audience. With converged years from 2008 to 2024, the Journal of Aerosol Medicine and Pulmonary Drug Delivery continues to serve as a vital platform for disseminating innovative research findings, clinical practice insights, and technological advancements in drug delivery systems, thereby significantly impacting therapeutic strategies for respiratory diseases.

EXPERT OPINION ON EMERGING DRUGS

Transforming insights into groundbreaking drug developments.
Publisher: TAYLOR & FRANCIS LTDISSN: 1472-8214Frequency: 4 issues/year

EXPERT OPINION ON EMERGING DRUGS, published by Taylor & Francis Ltd, stands at the forefront of the pharmacological sciences, focusing on the rapid development and evaluation of innovative therapeutic agents. With an impressive impact factor that reflects its contributions to the field, this journal is indexed under ISSN 1472-8214 and E-ISSN 1744-7623. The journal has consistently attained high recognition, currently holding a Q2 ranking in Pharmacology and a Q1 ranking in Pharmacology (medical) as of 2023, which places it within the top tiers of scholarly publications. Covering a broad range of topics related to emerging pharmaceuticals, it aims to bridge the gap between research and clinical practice by providing critical reviews, expert opinions, and insightful analyses. Based in the United Kingdom and actively published since 2000, the journal seeks to inform and inspire researchers, professionals, and students alike, offering a platform to foster collaboration and insight within the ever-evolving domain of drug development and pharmacotherapy.

CLINICAL PHARMACOLOGY & THERAPEUTICS

Advancing pharmacological knowledge for better patient care.
Publisher: WILEYISSN: 0009-9236Frequency: 6 issues/year

CLINICAL PHARMACOLOGY & THERAPEUTICS, published by WILEY, stands at the forefront of pharmacological research, serving as a pivotal resource for researchers, healthcare professionals, and students in the medical field. With its prestigious Q1 rating in both Pharmacology and Pharmacology (medical) categories, and ranking in the top 4% of journals in the field, it provides cutting-edge insights into drug therapy, pharmacokinetics, and innovative treatment strategies. The journal features a wide range of articles, from original research to comprehensive reviews, all aimed at advancing knowledge and clinical practice in pharmacology. With a publication history dating back to 1960 and continuing through 2024, its commitment to excellence is evident in its robust impact factor and high visibility in the academic community. For professionals striving to stay at the forefront of pharmacological advancements, CLINICAL PHARMACOLOGY & THERAPEUTICS remains an essential platform for disseminating and accessing vital research findings.

Clinical Pharmacology-Advances and Applications

Leading the Charge in Clinical Pharmacology Advances
Publisher: DOVE MEDICAL PRESS LTDISSN: 1179-1438Frequency: 1 issue/year

Clinical Pharmacology-Advances and Applications is a premier open access journal published by DOVE MEDICAL PRESS LTD, based in New Zealand. Since its establishment in 2009, the journal has been dedicated to advancing the field of pharmacology by disseminating innovative research and applications related to medication therapy and patient outcomes. With its notable impact factor and current ranking within the top percentile of pharmacology journals, it provides an invaluable platform for researchers, healthcare professionals, and students to share knowledge and foster collaboration. The journal's content spans a wide range of topics, ensuring coverage of both fundamental and emerging areas in medical pharmacology. As of 2023, it holds a strong position in the Q2 quartile, underscoring its relevance and influence within the scientific community. Authors and readers alike benefit from its open access model, which ensures that critical findings are widely accessible, thereby enhancing the pace of discovery and application in clinical settings.

FUNDAMENTAL & CLINICAL PHARMACOLOGY

Pioneering insights in pharmacology since 1987.
Publisher: WILEYISSN: 0767-3981Frequency: 6 issues/year

FUNDAMENTAL & CLINICAL PHARMACOLOGY is a distinguished journal dedicated to advancing the fields of pharmacology and clinical medicine. Published by WILEY, this journal serves as a pivotal platform for researchers, healthcare professionals, and students alike to disseminate innovative research findings and clinical applications. With an impressive history spanning from 1987 to 2024, it has consistently maintained its relevance in the scientific community, evidenced by its Q2 quartile ranking in both Pharmacology and Pharmacology (medical) categories for 2023. The journal's diverse publication range, which includes original research articles, reviews, and clinical studies, helps bridge the gap between fundamental research and practical application in healthcare settings. Although it does not offer open access, its rigorous peer-review process ensures that published content meets the highest scholarly standards, making it a vital resource for those aiming to stay at the forefront of pharmacological sciences.

JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

Exploring the Nexus of Pharmacology and Psychiatry for Enhanced Patient Care
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 0271-0749Frequency: 6 issues/year

JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, an esteemed publication from Lippincott Williams & Wilkins, serves as a vital resource in the fields of pharmacology and psychiatry. With a notable Q2 ranking in both the medical pharmacology and psychiatry categories, this journal facilitates the dissemination of significant findings related to psychopharmacological research, clinical practices, and advancements in mental health treatment. The journal has been committed to publishing high-quality, peer-reviewed articles since its inception in 1981, covering a wide scope of topics crucial for professionals, researchers, and students alike. With a current impact factor and burgeoning interest from the academic community, the JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY is essential for anyone engaged in the study or practice of clinical psychopharmacology, providing insights that shape contemporary psychiatric medication strategies and improve patient outcomes. For access, please refer to the official publication channels.

Reviews on Recent Clinical Trials

Transforming Clinical Knowledge into Practical Solutions.
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1574-8871Frequency: 4 issues/year

Reviews on Recent Clinical Trials, published by Bentham Science Publishers Ltd, is a distinguished journal in the medical and pharmacological fields, assessing the latest advancements in clinical research since its inception in 2006. With a focus on integrating multidisciplinary approaches to evaluating clinical trial methodologies, the journal caters to a diverse audience of researchers, professionals, and students keen on enhancing their knowledge and understanding of innovative therapeutic strategies and drug developments. Notably positioned in the Q3 quartile as ranked by Scopus for both 'Medicine (miscellaneous)' and 'Pharmacology', the journal illustrates a growing academic influence, evidenced by its Scopus rankings—holding a commendable 72nd percentile in general medicine and a 33rd percentile in pharmacology. While the journal is not open access, it remains committed to disseminating high-quality, peer-reviewed content that drives forward the conversation in clinical research. For those interested in staying abreast of novel findings and comprehensive reviews within the clinical trial landscape, Reviews on Recent Clinical Trials stands out as an essential resource.

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Exploring the intersection of drug safety and epidemiology.
Publisher: WILEYISSN: 1053-8569Frequency: 12 issues/year

Pharmacopidemiology and Drug Safety is a prestigious academic journal published by Wiley, dedicated to exploring the field of pharmacology and epidemiological studies since its inception in 1992. With its ISSN 1053-8569 and E-ISSN 1099-1557, the journal has achieved notable recognition, ranking Q2 in Epidemiology and Q1 in Medical Pharmacology in the 2023 category quartiles. Its Scopus rankings further enhance its reputation, placing it at 105th in the field of pharmacology and at 63rd in epidemiology, reflecting its commitment to publishing high-quality research that informs clinical practices and public health policies. Although it operates under a subscription model rather than open access, Pharmacopidemiology and Drug Safety plays a critical role in disseminating vital knowledge regarding drug safety and effectiveness, making it an essential resource for researchers, professionals, and students looking to stay at the forefront of advancements in the medical field.

CHEMOTHERAPY

Exploring Breakthroughs in Drug Discovery and Oncology
Publisher: KARGERISSN: 0009-3157Frequency: 4 issues/year

CHEMOTHERAPY, published by KARGER, is a premier academic journal established in 1960, dedicated to disseminating cutting-edge research and advancements in the fields of drug discovery, infectious diseases, oncology, and pharmacology. With an impressive Scopus ranking placing it in the Q2 category for major disciplines such as Drug Discovery and Infectious Diseases, this journal provides an invaluable platform for researchers and professionals aiming to explore new therapeutic approaches and methodologies. Located in the heart of Switzerland, its publications are a key resource for anyone looking to stay informed about the latest developments and trends in the pharmacological sciences. Researchers can benefit from its diverse scope while contributing to a growing body of knowledge that emphasizes the importance of effective chemotherapeutic strategies in modern medicine. Despite not being an Open Access journal, CHEMOTHERAPY remains committed to maintaining a rigorous peer-review process, ensuring the highest quality of published work.

JOURNAL OF CLINICAL PHARMACOLOGY

Advancing the Science of Drug Therapy
Publisher: WILEYISSN: 0091-2700Frequency: 12 issues/year

Welcome to the Journal of Clinical Pharmacology, an esteemed publication in the field of pharmacology and medical pharmacology, published by Wiley. Since its inception in 1973, this journal has been at the forefront of disseminating innovative research findings and comprehensive reviews that enhance our understanding of drug therapies and their clinical applications. With an impact factor that reflects its strong reputation and a Scopus ranking placing it in the 64th percentile among 272 journals in medical pharmacology, the journal stands as a critical resource for researchers, healthcare professionals, and students alike. Although currently not an Open Access journal, it provides invaluable insights into therapeutic drug use and safety, the pharmacokinetics of drugs, and the development of new therapeutic strategies. The journal's commitment to advancing the field through high-quality, peer-reviewed articles ensures it remains a vital asset in the continuously evolving landscape of clinical pharmacology.